Trial Profile
Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects With Painful Lumbar Radiculopathy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2015
Price :
$35
*
At a glance
- Drugs Neublastin (Primary) ; Neublastin (Primary)
- Indications Radiculopathy
- Focus Adverse reactions
- Sponsors Biogen Idec
- 08 Feb 2015 Status changed from discontinued to completed as per ClinicalTrials.gov record.
- 31 Dec 2014 New trial record